Daniela Tudor
Overview
Explore the profile of Daniela Tudor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
705
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cottignies-Calamarte A, Tudor D, Bomsel M
Front Immunol
. 2023 Feb;
14:1037033.
PMID: 36817447
Recent advances in the development of therapeutic antibodies (Abs) have greatly improved the treatment of otherwise drug-resistant cancers and autoimmune diseases. Antibody activities are mediated by both their Fab and...
2.
Ruiz M, Siracusano G, Cottignies-Calamarte A, Tudor D, Real F, Zhu A, et al.
Front Immunol
. 2022 Oct;
13:842468.
PMID: 36248831
Highlights: Mucosal pulmonary antibody response in COVID-19 outcome remains unclear. We show that in severe COVID-19 patients, mucosal pulmonary non-neutralizing SARS-CoV-2 IgA persit after viral clearance in the lung. Furthermore,...
3.
Xu L, Tudor D, Bomsel M
Front Immunol
. 2021 Feb;
11:599278.
PMID: 33613520
Mucosal nasal vaccine development, although ideal to protect from pathogens invading mucosally, is limited by the lack of specific adjuvant. We recently used P1, a conserved region of HIV-1 gp41-envelope...
4.
Khamassi M, Xu L, Rey J, Duchemin M, Bouceba T, Tuffery P, et al.
PLoS Pathog
. 2020 Dec;
16(12):e1009103.
PMID: 33315937
The antibody molecule comprises a variable domain conferring antigen specificity and affinity distinct from the heavy chain constant (CH) domains dictating effector functions. We here interrogate this paradigm by evaluating...
5.
Duchemin M, Tudor D, Cottignies-Calamarte A, Bomsel M
Front Immunol
. 2020 Jun;
11:1141.
PMID: 32582208
Antibodies mediate a broad array of non-neutralizing Fc-mediated functions against HIV-1 including antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). Accordingly, ADCC and ADCP induced by anti-HIV envelope gp120...
6.
Ganor Y, Real F, Sennepin A, Dutertre C, Prevedel L, Xu L, et al.
Nat Microbiol
. 2019 Feb;
4(4):633-644.
PMID: 30718846
Human immunodeficiency virus type 1 (HIV-1) eradication is prevented by the establishment on infection of cellular HIV-1 reservoirs that are not fully characterized, especially in genital mucosal tissues (the main...
7.
Duchemin M, Khamassi M, Xu L, Tudor D, Bomsel M
Front Immunol
. 2018 Apr;
9:244.
PMID: 29651286
The protective efficacy of human immunodeficiency virus-1 (HIV-1) antibodies (Abs) remains mostly correlated with their neutralizing activity engaging their Fab region. However, anti-HIV-1 Abs also mediate a broad array of...
8.
Tudor D, Margaritescu S, Sanchez-Ramirez S, Robinson S, Cooper P, Moncalvo J
Fungal Biol
. 2014 Aug;
118(8):732-42.
PMID: 25110135
This study confirms that the two known Chlorociboria species from North America correspond to Chlorociboria aeruginascens and Chlorociboria aeruginosa that were originally described from Europe. The anamorphs of these two...
9.
Ganor Y, Drillet-Dangeard A, Lopalco L, Tudor D, Tambussi G, Barry Delongchamps N, et al.
J Exp Med
. 2013 Oct;
210(11):2161-70.
PMID: 24081951
Upon its mucosal entry, human immunodeficiency virus type 1 (HIV-1) is internalized by Langerhans cells (LCs) in stratified epithelia and transferred locally to T cells. In such epithelia, LCs are...
10.
Brombin C, Diomede L, Tudor D, Drillet A, Pastori C, Poli E, et al.
PLoS One
. 2013 Mar;
8(3):e58768.
PMID: 23533590
This work aims at identifying a set of humoral immunologic parameters that improve prediction of the activation process in HIV patients. Starting from the well-known impact of humoral immunity in...